View Older Stories View More Recent Stories
-
Iconix Investors: Lieff Cabraser Reminds Investors of Upcoming Deadline in Class Action Litigation - ICON
-
Roth Capital Starts Global Water Resources (GWGWF) at Buy
-
Roth Capital Downgrades Golden Minerals Company (AUMN) to Neutral
-
RedHill Biopharma (RDHL) Prices 2.46M Public Offering at $16.25/ADS
-
RedHill Biopharma Prices Public Offering of Its American Depository Shares
-
Delcath Systems (DCTH) Prices 9.35M Public Offering at $0.75/Unit
-
Delcath Announces Pricing Of Public Offering
-
Roth Capital Raises the Price Target on Middleby Corp (MIDD) Ahead of AGA Rangemaster Acquisition
-
Roth Capital Sees Compelling Entry Point in uniQure BV (QURE) Ahead of Data Readouts
-
MEDIGUS ANNOUNCES COMPLETION OF $7.1 MILLION PUBLIC OFFERING
-
MEDIGUS ANNOUNCES COMPLETION OF $7.1 MILLION PUBLIC OFFERING
-
NeuroDerm Ltd. Announces Pricing of Public Offering
-
NeuroDerm Ltd. Announces Pricing of Public Offering
-
Streetinsider.com's Hot Lunchtime Reads 7/15: (M) (BLRX) (ARCP) (TBT)
-
BioLineRx (BLRX) Bullish Stance Reiterated at Roth Capital Ahead of Data Release
-
RedHill Biopharma (RDHL) to Offer 1.8M ADSs
-
RedHill Biopharma Announces Size of Proposed Public Offering of Its American Depository Shares
-
ANI Pharmaceuticals (ANIP) PT Bumped to $70 at Roth Capital
-
Macrogenics (MGNX) Prices Larger 3.53M Common Stock Offering at $37/Share
-
MacroGenics Announces Pricing of Public Offering of Common Stock
-
MacroGenics Announces Pricing of Public Offering of Common Stock
-
RedHill Biopharma (RDHL) Plans ADS Offering
-
RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares
-
Roth Positive on Cytokinetics (CYTK) Following Phase III VITALITY-ALS Initiation
-
Roth Positive on Ballard Power's (BLDP) Protonex Acquisition; Offers Commentary
-
Vermillion (VRML) Prices 8.35M Common Stock Offering at $1.96/Share
-
Vermillion, Inc. Prices $16.4 Million Public Offering of Common Stock
-
Tonix Pharmaceuticals (TNXP) Prices 2.33M Common Stock Offering at $7.50/Share
-
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
-
Cempra (CEMP) Added to Focus List at Roth Capital
-
DepoMed (DEPO) PT Raised to $33 at Roth Capital on Expected Higher Bid
-
Roth Capital Raises Price Target on PriceSmart (PSMT) Following 3Q15 Results
-
Roth Capital Maintains Neutral on ZAGG, Inc. (ZAGG) Ahead of 2Q15 Results
-
Vermillion (VRML) Plans Public Offering of Common Stock
-
Tonix Pharmaceuticals (TNXP) Plans Common Stock Offering
-
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Vermillion, Inc. Announces Proposed Public Offering of Common Stock
-
Ohr Pharmaceutical (OHRP) Bullish Stance Reiterated at Roth Capital Following Encouraging Data
-
Roth Capital Raises Price Target on NeoGenomics (NEO) Ahead of Potential Reimbursement Changes
-
Roth Capital Raises Price Target on Increased Demand in Trecora Resources (TREC)
-
bluebird bio (BLUE) Summer Sell-Off Creates Attractive Entry Point, Roth Capital Says
-
Roth Capital Reiterates Buy Rating on Intel (INTC) Ahead of 2Q15 Reports
-
Recent Dip in CECO Environmental (CECE) Creates Buying Opportunity - Roth Capital
-
Eco-stim Energy Solutions (ESES) Prices 5.5M Common Stock Offering at $4.75/Share
-
Eco-Stim Energy Solutions Announces Pricing of Public Offering of Common Stock
-
Eco-Stim Energy Solutions Announces Pricing of Public Offering of Common Stock
-
Roth Capital Resumes AcelRx Pharmaceuticals (ACRX) at Buy
-
Final Results of First Administrative Review of 2012 Tariffs Rule Worse than Expected - Roth (YGE) (FSLR) (TSL)
-
Notable Analyst Rating Changes 7/9: (TRV) (MBLY) (JBHT) Upgraded; (SHAK) (REGN) (VR) Downgraded
-
Roth Capital Remains Sidelined as Stock in PTC Therapeutics (PTCT) is Down ~14% YTD

